Please use this identifier to cite or link to this item:
|Title:||Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility study|
|Authors:||THIJSEN L.; SCHAART D.r.; DE VRIES D.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DENKOVA A.g.|
|Citation:||RADIOCHIMICA ACTA vol. 100 no. 7 p. 473-481|
|Type:||Articles in periodicals and books|
|Abstract:||Targeted alpha therapy has shown promising pre-clinical and clinical results in the fight against cancer. The use of in vivo generators, generating a highly cytotoxic cascade of alpha particles, is attracting increasing interest for clinical application. 225Ac is one of the nuclides that can serve as an in vivo generator. It is commercially available and provides four alpha particles with a total energy of 28 MeV per 225Ac decay. However, its alpha emitting daughter nuclides may escape from the target region due to recoil and cause unwanted toxicity in other parts of the body. In this paper, we investigate the feasibility of designing spherical, block-copolymer based nano-carriers (polymersomes) to retain the recoiling daughter nuclides. A Monte Carlo code, called NANVES, has been developed to simulate the range distributions of recoil atoms in different materials and to determine the optimum nano-carriers design. Recoil ranges in planar polystyrene films were determined experimentally and compared to simulations of the experiment, indicating that NANVES may provide accurate results. Simulations of various nano-carriers designs indicate that double-layered polymersomes with a diameter of 800 nm are capable of completely retaining the first daughter nuclide 221Fr, while the escape fraction of the third radioactive daughter 213Bi is reduced to 20 % and the percentage of alpha particles emitted from escaped daughter products outside the nano-carriers is less than 10 %.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.